



# Putting Open Innovation Into Practice

Pierre Meulien- Executive Director- Innovative Medicines Initiative (IMI)  
Pharmaceutical Sciences World Congress 2017 Stockholm Sweden

# What is Open Innovation?

## Henry Chesbrough (2003)

“Open innovation is a paradigm that assumes that firms can and should use external ideas as well as internal ideas, and internal and external paths to market, as the firms look to advance their technology. Open innovation combines internal and external Ideas into architectures and systems whose requirements are defined by a business model.”



# Implementing Open Innovation




“... involving far more actors in the innovation process, from researchers, to entrepreneurs, to users, to governments and civil society.”

“We need open innovation to capitalise on the results of European research and innovation. This means creating the right ecosystems, increasing investment, and bringing more companies and regions into the knowledge economy.”

Carlos Moedas, European Commissioner for Research, Science and Innovation  
- 2016

# Why do we need new collaborative models in healthcare?

Because drug development is very...



Because...

- Biological mechanisms underlying disease are complex
- Clinical trial designs need to be adapted to scientific knowledge
- Regulatory pathways need be adapted in certain cases


# IMI – Europe's partnership for health

## IMI1: 2008-2013

€2 bn budget  
59 projects

## IMI2: 2014-2020

€3.3 bn budget  
More ambitious  
More open  
Greater scope




# IMI – Europe's partnership for health

## IMI mission

IMI facilitates open collaboration in research to advance the development of, and accelerate patient access to, personalised medicines for the health and wellbeing of all, especially in areas of unmet medical need.

# Distribution of funding per scientific area – IMI1



EFPIA contributions



IMI contributions

# An international, cross-sector community



**Over 9 000 researchers** working for:

- open collaboration
- improved R&D productivity
- innovative approaches to unmet medical needs

# Measures of Success

New models  
developed &  
published

Setting new  
standards

Use  
by industry

Impact on  
regulatory  
framework

Better drugs  
and impact on  
medical  
practice

**Better Science = Evidence based  
decision making**

# IMI – Ecosystem for innovative collaborations

- Allow engagement in a cross-sector and multi-disciplinary consortium at the forefront of cutting-edge research
- Provide the necessary scale by combination of funding, expertise, knowledge, skills and resources
- Build a trustful collaboration upon a creative spirit, innovative and critical thinking
- Gain from each others (new knowledge, skills, ways of working)
- Be transformative to make a difference in drug development and ultimately patients' lives
- Communicate the societal value of this type of model

IMI is a **neutral platform** where **all involved** in drug development can engage in **open collaboration** on **shared challenges**.



**infodesk@imi.europa.eu**

[www.imi.europa.eu](http://www.imi.europa.eu)

 @IMI\_JU